{
    "clinical_study": {
        "@rank": "43584", 
        "arm_group": {
            "arm_group_label": "S-1 plus Abraxane", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, \u22671.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment."
        }, 
        "brief_summary": {
            "textblock": "This phase II study was designed to evaluate the efficacy and safety of S-1 plus Abraxane as\n      second-line treatment for cholangiocarcinoma."
        }, 
        "brief_title": "S-1 in Combination With Abraxane in Treating Cholangiocarcinoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cholangiocarcinoma", 
        "condition_browse": {
            "mesh_term": "Cholangiocarcinoma"
        }, 
        "detailed_description": {
            "textblock": "There are no standard second-line treatment for cholangiocarcinoma, new therapies are\n      needed. The efficacy of S-1 as first-line treatment for cholangiocarcinoma was confirmed in\n      several studies. The IMPACT study showed that Abraxane plus gemcitabine provide better\n      survival than gemcitabine alone. Since cholangiocarcinoma displayed similar sensitivity to\n      chemotherapy which was used in pancreatic carcinoma, we assume that S-1 plus Abraxane is\n      effective and safe in treating cholangiocarcinoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic or cytologic diagnosis of cholangiocarcinoma\n\n          -  Not eligible for curative surgery\n\n          -  Progressed after first-line gemcitabine-based chemotherapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 2 or better\n\n          -  No serious or uncontrolled concomitant medical illness\n\n          -  Adequate bone marrow function (absolute neutrophil count \u22671,500 ul, platelet count\n             \u226790,000/ul), hemoglobin: > or equal to 8 mg/dL, total bilirubin: < or equal to 1.5 X\n             institutional upper limit of normal, calculated creatinine clearance greater than or\n             equal to 60 mL/min (calculated by the Cockcroft and Gault method).\n\n        Exclusion Criteria:\n\n          -  Uncontrolled infection or severe active comorbid disease\n\n          -  Previous malignancy in the past five years, excluding nonmelanoma skin cancers and in\n             situ cervical, bladder or uterine cancer\n\n          -  Pregnancy or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963325", 
            "org_study_id": "S1vsNab-P20130819"
        }, 
        "intervention": {
            "arm_group_label": "S-1 plus Abraxane", 
            "description": "Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, \u22671.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.", 
            "intervention_name": "S-1 plus Abraxane", 
            "intervention_type": "Drug", 
            "other_name": [
                "Paclitaxel Albumin-Bound Particles for Injectable Suspension", 
                "Gimeraciland Oteracil Porassium Capsules"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Abraxane Plus S-1 as Second-line Treatment for Cholangiocarcinoma", 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Yuhong Li, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response rates", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963325"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Yuhong Li", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Adverse events evaluated by Common Terminology Criteria for Adverse Events v3.0.", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhong Li", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}